These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

849 related items for PubMed ID: 25959100

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Radiopharmaceuticals used for diagnosis and therapy of NETs.
    Papachristou M.
    Hell J Nucl Med; 2023; 26 Suppl():19-20. PubMed ID: 37658556
    [Abstract] [Full Text] [Related]

  • 3. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME.
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with 68Ga-DOTATATE and 18F-FDG and Multimodality Anatomic Imaging in Metastatic Neuroendocrine Tumors of Unknown Primary in a PRRT Workup Setting.
    Sampathirao N, Basu S.
    J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
    [Abstract] [Full Text] [Related]

  • 6. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P, Ranade R, Ostwal V, Shrikhande SV, Goel M, Basu S.
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [Abstract] [Full Text] [Related]

  • 7. Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy.
    Zhang J, Liu Q, Singh A, Schuchardt C, Kulkarni HR, Baum RP.
    J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
    [Abstract] [Full Text] [Related]

  • 8. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
    Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C.
    Recent Results Cancer Res; 2013 Nov; 194():353-71. PubMed ID: 22918768
    [Abstract] [Full Text] [Related]

  • 9. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of 177Lu-DOTATATE PRRT: Does In Vivo Molecular PET Perform Better from the Viewpoint of Prediction of Tumor Biology?
    Adnan A, Basu S.
    J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476
    [Abstract] [Full Text] [Related]

  • 10. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
    Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C.
    J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
    [Abstract] [Full Text] [Related]

  • 11. Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience - do we need [18F]FDG PET/CT for qualification to PRRT?
    Zemczak A, Kołodziej M, Gut P, Królicki L, Kos-Kudła B, Kamiński G, Ruchała M, Pawlak D, Kunikowska J.
    Endokrynol Pol; 2020 Dec; 71(3):240-248. PubMed ID: 32293704
    [Abstract] [Full Text] [Related]

  • 12. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV, Talole S, Prabhash K, Basu S.
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [Abstract] [Full Text] [Related]

  • 13. Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors.
    Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, Langer SW, Elema DR, Kjaer A.
    J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
    [Abstract] [Full Text] [Related]

  • 14. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature.
    Johnbeck CB, Knigge U, Kjær A.
    Future Oncol; 2014 Nov; 10(14):2259-77. PubMed ID: 25471038
    [Abstract] [Full Text] [Related]

  • 15. Prevalence of hitherto unknown brain meningioma detected on 68Ga-DOTATATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of 177Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors.
    Parghane RV, Talole S, Basu S.
    World J Nucl Med; 2019 Nov; 18(2):160-170. PubMed ID: 31040748
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours.
    Severi S, Nanni O, Bodei L, Sansovini M, Ianniello A, Nicoletti S, Scarpi E, Matteucci F, Gilardi L, Paganelli G.
    Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):881-8. PubMed ID: 23443937
    [Abstract] [Full Text] [Related]

  • 19. Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis.
    Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W.
    Acta Radiol; 2014 May; 55(4):389-98. PubMed ID: 23928010
    [Abstract] [Full Text] [Related]

  • 20. Multimodal Imaging of 2-Cycle PRRT with 177Lu-DOTA-JR11 and 177Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model.
    Albrecht J, Exner S, Grötzinger C, Prasad S, Konietschke F, Beindorff N, Kühl AA, Prasad V, Brenner W, Koziolek EJ.
    J Nucl Med; 2021 Mar; 62(3):393-398. PubMed ID: 32859703
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.